to Oslo Medtech
Register here to subscribe to our newsletter!
Generating innovation. For better living and health.
”CE godkjenning og QA-Reg guidelines for Medtech-gründere”
‘Auditoriet’, Resepsjon Syd /Veritas 2, Det Norske Veritas, Veritasveien 1, 1363 Høvik, Bærum
The distribution agreement with In-Vivo Aps has been terminated and MediStim is in process of recruiting for a direct sales organization in Denmark.
Oslo Medtech gratulerer Otivio AS, Novelda AS , Bakteriefritt AS, Sintef, Abilia, Imatis, Hjelp 24 og Geria med gode søknader og samfunnsnyttig prosjektfokus!
De konstruktive samarbeidsprosjektene mellom bedrift, forskning og helseinstitusjon vil kunne bidra til å redusere utfordringene i helsesektoren. Innovasjonsbedriftene har fått innvilget midler fra Regionale forskningsfonds (RFF) utlysning knyttet til ”Samfunnets behov for helse- og omsorgstjenester og teknologi for den aldrende befolkningen”.
The project involves several Oslo Medtech members; the host Oslo University Hospital has Simula Research Laboratory as research partner and GE Vingmed Ultrasound AS, CardioSolv LLC, Biosense Webster Ltd and Kalkulo AS as company partners.
The Centre for Cardiological Innovation aims to be a world leader in research on ultrasound-based diagnosis.
Smarthusteknologi for omsorgsboliger i Oslo Kommune”
Tid: Mandag 31. januar 2011, kl 15:00 – 18:00 Sted: Møterom VIA, Forskningsparken, Gaustadalléen 21, 0349 Oslo
Tid: Mandag 31. januar 2011, kl 15:00 – 18:00 Sted: Møterom VIA, Forskningsparken, Gaustadalléen 21, 0349 Oslo. Se kartlink og veibeskrivelse Oslo Medtech
Tid: Torsdag 27. januar 2010, kl 08:00 – 10:00 Sted: Møterom VIA, Forskningsparken, Gaustadalléen 21, 0349 Oslo
ENIAC Joint Undertaking (www. Eniac.eu) will issue the fourth call for proposals in spring 2011, and new project ideas will be discussed at a brookerage event in Berlin 1-2 February. ENIAC JU is funding research within nanoelectronics including sensors, and one of the application areas is “Health and the Aging Society”. The 2011 call will focus on “Home Healthcare” and “Hospital Healthcare”.
OstomyCure AS, a company focused on developing novel products for stoma patients, announces that it has appointed Geir Christian Melen as its Chief Executive Officer (CEO). At OstomyCure, Mr. Melen will be responsible for the development and commercialization of TIES®, a proprietary implant system focused on dramatically improving the lives of stoma patients. "I look forward to joining OstomyCure at a time of great potential", Geir Christian Melen commented. - OstomyCure has embarked on the clinical development phase for TIES® and I believe this new medical device can be brought successfully to market on an international basis.